

MAP65, Inc.

Terms of Service — Clinical Partners Program

Version 1.2

Effective Date: July 8, 2026

Published by MAP65, Inc. These Terms govern all Clinical Partners Program subscriptions (Tier 1 Associate, Tier 2 Partner, Tier 3 Founder) and any individual accessing the MAP65 platform or services. The current version of these Terms is available at www.MAP65.com/terms.

These Terms of Service ("Terms") constitute a legally binding agreement between MAP65, Inc. ("MAP65," "we," "us," or "our") and the subscribing institution, named user, or individual (collectively, "Subscriber") accessing or using the MAP65 platform or services. By placing a purchase order, signing a quotation, accessing the MAP65 platform, or using any MAP65 service, Subscriber agrees to be bound by these Terms in their entirety. If Subscriber is accepting these Terms on behalf of an institution or employer, Subscriber represents that it has authority to bind that entity. If Subscriber does not agree to these Terms, it must not use the services.

1. Definitions

The following defined terms apply throughout these Terms:

"Services"	The MAP65 web-based video platform, annotated surgical video content, associated software tools, and any related services provided by MAP65 under a Subscription.
"Platform"	The MAP65 secure web application and associated infrastructure through which annotated video content and related tools are delivered.
"Content"	All video recordings, annotation data, metadata, teaching points, labels, overlays, documentation, and other materials made available to Subscriber through the Platform.
"MAP65 Library Content"	Content created, curated, or annotated by or on behalf of MAP65, including the shared robotic thoracic surgery annotated video library and the unannotated video library described in Section 2.1. Access to annotated MAP65 Library Content is tier-dependent: Tier 1 (Associate) subscribers receive access to the right upper lobe (RUL) lobectomy case; Tier 2 (Partner) subscribers receive access to one annotated video per lobe; and Tier 3 (Founder) subscribers receive access to the full annotated library as it develops. The unannotated video library is included for all Tiers.
"Subscriber-Submitted Content"	Video recordings, metadata, or other materials submitted by Subscriber or its Named Users to MAP65 for annotation or storage via the Platform.
"Annotation Data"	All labels, tags, structural annotations, anatomical contours, critical structure identifiers, and associated metadata generated by MAP65 in connection with any Content, whether MAP65 Library Content or Subscriber-Submitted Content. Note: dynamic annotation layers (procedural phases, risk patterns, workflow deviations) are potential future roadmap items and are not included in the current pre-commercial product scope.
"Named User"	A specific, identified individual authorized to access the Platform under a Subscription, up to the seat limit for the applicable tier.
"Subscription"	A time-limited, non-exclusive license to access and use the Services, purchased under a Quotation or Order Form, at the selected tier.
"Subscription Term"	The period beginning on the subscription start date and continuing for the minimum term (1 year) plus any renewal periods.

"Tier"	The service level selected by Subscriber: Tier 1 (Associate), Tier 2 (Partner), or Tier 3 (Founder), each with distinct features, pricing, and data rights as described in the applicable Quotation and these Terms.
"De-Identified"	Processed to remove or obscure all information that could reasonably be used to identify a patient, in compliance with 45 C.F.R. § 164.514 (HIPAA Expert Determination or Safe Harbor) or equivalent applicable standard.
"AI Model"	Any machine learning model, neural network, computer vision system, or related artificial intelligence system developed, trained, fine-tuned, or validated by MAP65, including the Second Surgeon intraoperative clinical decision support platform.
"Derivative Works"	Any work that is based upon, derived from, processed from, or incorporates Subscriber-Submitted Content in whole or in part, including without limitation annotated versions of submitted video, extracted frames or clips, structural and anatomical labels, training datasets compiled in whole or in part from Subscriber-Submitted Content, and any AI Model weights, parameters, or outputs trained or fine-tuned using Subscriber-Submitted Content. MAP65 owns all right, title, and interest in Derivative Works, subject to the underlying rights Subscriber retains in the original Subscriber-Submitted Content, as further described in Section 3.3.
"Post-Clearance Product"	Any MAP65 product or service that has received marketing authorization from the U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory authority.

2. Subscription, Access, and Permitted Use

2.1 License Grant

Subject to payment of all applicable fees and compliance with these Terms, MAP65 grants Subscriber a limited, non-exclusive, non-transferable, non-sublicensable license during the Subscription Term to: (a) access and use the Platform for the number of Named Users permitted under the selected Tier; (b) view, stream, and use annotated MAP65 Library Content at the access level corresponding to the selected Tier (Tier 1: RUL lobectomy case; Tier 2: one annotated video per lobe; Tier 3: full annotated library as published); (c) view, stream, and use the unannotated video library, included for all Tiers; (d) for Partner (Tier 2) and Founder (Tier 3) tier subscribers, access institution-specific Annotation Data returned by MAP65 under the applicable case volume limit; and (e) for any Tier, access additional à la carte annotated cases purchased under Section 2.4; in each case solely for the Permitted Purposes set forth in Section 2.2.

2.2 Permitted Purposes

Content may be used solely for the following purposes ("Permitted Purposes"):

- Surgical education, residency and fellowship training, and continuing medical education for Named Users;
- Preparation for, review of, and teaching related to robotic thoracic surgical procedures;
- Internal quality improvement and peer review activities conducted by Named Users at the subscribing institution;
- Non-commercial academic research, including participation in MAP65-led or MAP65-affiliated research collaborations as expressly authorized in writing by MAP65; and
- Evaluation of the Second Surgeon platform concept and provision of feedback to MAP65 as contemplated by the Partnership program.

2.3 Restrictions

Subscriber shall not, and shall ensure Named Users do not:

- Use the Content or Platform for any clinical, diagnostic, or treatment decision-making purpose during live surgical procedures, except where expressly authorized in writing by MAP65 and permitted by applicable regulatory clearance;
- Reproduce, copy, distribute, publish, transmit, display, sublicense, sell, or otherwise commercially exploit any Content or Annotation Data;
- Share, transfer, or make available access credentials or Content to any person who is not a Named User under the Subscription;
- Reverse engineer, decompile, disassemble, or attempt to derive source code or training data from any Platform component or AI Model;

- Remove, obscure, or alter any copyright notices, attribution statements, watermarks, or terms of service references embedded in Content;
- Use the Platform or Content in any manner that violates applicable law, including HIPAA, export control regulations, or applicable clinical data protection requirements;
- Use any automated tools, bots, scrapers, or scripts to access or extract Content from the Platform; or
- Use the Services to develop, train, or improve any AI model or commercial product that competes with any MAP65 product or service.

2.4 À La Carte Add-On Annotation

Subscribers at any Tier may purchase additional institution-specific annotated cases beyond their Tier's included allotment (Tier 2: up to 10 cases/yr included; Tier 3: up to 10 cases/yr included) on an à la carte basis at MAP65's then-current per-case rate (currently \$2,000 per case, subject to change with sixty (60) days written notice). À la carte cases are subject to the same data rights, de-identification obligations, and permitted use restrictions as institution-specific cases included in a Tier 2 or Tier 3 subscription. For Tier 1 (Associate) Subscribers, purchase of three (3) or more à la carte cases in any twelve-month period constitutes a natural upgrade trigger, and MAP65 may offer a Tier 2 upgrade at a pro-rated fee credit equal to the à la carte fees paid in that period. Note: videos submitted to MAP65 for annotation may, following de-identification, be incorporated into the MAP65 shared video library and made accessible to other subscribers at applicable tier access levels.

2.5 Tier Upgrades

Subscriber may upgrade to a higher Tier at any time during the Subscription Term. Upon upgrade: (a) the new Tier pricing applies on a pro-rated basis for the remainder of the then-current annual period, with any prepaid fees for the lower Tier credited toward the upgrade fee; (b) the higher Tier features and case volume limits take effect immediately; and (c) the Subscription Term does not reset. Downgrades are not permitted mid-term; a Subscriber wishing to move to a lower Tier may do so at the next annual renewal with sixty (60) days written notice.

2.6 Video Upload Credit

Subscriber may earn a credit of \$25 per full-length robotic surgery video uploaded to the Platform, regardless of Tier, where such video meets MAP65's upload specifications and de-identification requirements then in effect. Accrued credits may be applied toward up to fifty percent (50%) of Subscriber's subscription fee for the following annual period and do not carry forward beyond that period; unused credits expire at the end of the annual period in which they were earned. Credits have no cash value, are non-transferable, and are subject to MAP65's reasonable verification that uploaded video meets applicable quality and de-identification standards. Video uploaded to earn a credit under this Section is Subscriber-Submitted Content and is subject to the license-back and other provisions of Section 3. Note: videos uploaded to the Platform may, following de-identification, be incorporated into the MAP65 shared video library and made accessible to other subscribers at applicable tier access levels.

3. Data Rights, Intellectual Property, and License-Back

3.1 MAP65 Ownership of Content

All MAP65 Library Content, Annotation Data generated by MAP65, Platform software, and associated intellectual property are and remain the exclusive property of MAP65, Inc. These Terms do not transfer any ownership interest to Subscriber. MAP65 reserves all rights not expressly granted.

3.2 Subscriber-Submitted Content — Ownership

Subscriber retains ownership of Subscriber-Submitted Content (e.g., operative video recordings submitted for institution-specific annotation). However, by submitting any content to MAP65 for annotation or processing, Subscriber grants MAP65 the rights described in Sections 3.3 and 3.4.

3.3 License-Back: Annotation and AI Training Rights

By submitting Subscriber-Submitted Content to MAP65 — whether as an included institution-specific case under Tier 2 or Tier 3, as an à la carte annotated case under Section 2.4, as a video uploaded for credit under Section 2.6, or otherwise — Subscriber grants MAP65, Inc. a perpetual, irrevocable, worldwide, royalty-free, sublicensable license to:

(a) access, process, (semi-)manually or AI-assistedly annotate, and create Derivative Works of Subscriber-Submitted Content for the purpose of generating Annotation Data and other derived outputs; (b) own all right, title, and interest in and to such Derivative Works, including all Annotation Data, labels, structural identifications, training datasets, and any other content generated by or derived from Subscriber-Submitted Content through MAP65's annotation, processing, or AI training activities, subject only to the underlying rights Subscriber retains in the original Subscriber-Submitted Content itself; (c) use De-Identified Subscriber-Submitted Content, Derivative Works, and all associated Annotation Data to train, develop, fine-tune, validate, and improve any MAP65 AI Model, including the Second Surgeon platform; (d) incorporate De-Identified Subscriber-Submitted Content, Derivative Works, and Annotation Data into the MAP65 shared video library for access by other Subscribers at applicable tier access levels, subject to the de-identification requirements described herein; and (e) use De-Identified Subscriber-Submitted Content, Derivative Works, and Annotation Data in academic publications, conference presentations, regulatory submissions (including FDA 510(k) and De Novo submissions), and investor materials, provided that no Subscriber-Submitted Content or Derivative Work is disclosed in a form that would identify any individual patient or the submitting institution without prior written consent. "Derivative Works" means any work that is based upon, derived from, processed from, or incorporates Subscriber-Submitted Content in whole or in part, including without limitation annotated versions of submitted video, extracted frames or clips, structural and anatomical labels, training datasets compiled in whole or in part from Subscriber-Submitted Content, and any AI model weights, parameters, or outputs trained or fine-tuned using Subscriber-Submitted Content.

3.4 Condition: De-Identification

The license in Section 3.3 is conditioned on MAP65's obligation to De-Identify all Subscriber-Submitted Content prior to any use beyond delivery of annotated content back to Subscriber. MAP65 will not use identifiable patient data for AI training, library inclusion, or any purpose other than completing the annotation service for which it was submitted. Subscriber represents and warrants that all Subscriber-Submitted Content submitted to MAP65 has been De-Identified by Subscriber prior to upload, in compliance with HIPAA and applicable law. MAP65 does not accept identifiable patient data.

3.5 MAP65 Library Content — Use in Shared Library

MAP65 Library Content created by MAP65 (not Subscriber-Submitted Content) may be made available to all Subscribers at the applicable access tier without restriction or compensation to Subscriber.

3.6 Annotation Data Generated from Subscriber-Submitted Content

Annotation Data generated by MAP65 in connection with Subscriber-Submitted Content is jointly useful to both parties. MAP65 grants Subscriber a perpetual, non-exclusive, royalty-free license to use Annotation Data returned via the Platform for Permitted Purposes. MAP65 retains full rights to all Annotation Data as set forth in Section 3.3.

3.7 Feedback

Any feedback, suggestions, product input, or ideas provided by Subscriber or Named Users to MAP65 regarding the Platform, Content, or any MAP65 product or service ("Feedback") may be used by MAP65 for any purpose without obligation or compensation to Subscriber. Subscriber assigns to MAP65 all rights in any Feedback.

3.8 Reserved

This section is reserved for future supplemental data governance arrangements outside the scope of this commercial agreement.

4. Disclaimer of Warranties

THE SERVICES, PLATFORM, AND ALL CONTENT (INCLUDING ALL MAP65 LIBRARY CONTENT, ANNOTATION DATA, AND SUBSCRIBER-SUBMITTED CONTENT RETURNED WITH ANNOTATIONS) ARE PROVIDED "AS IS" AND "AS AVAILABLE" WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. MAP65 EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING BUT NOT LIMITED TO: (a) ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT; (b) ANY WARRANTY THAT THE CONTENT IS ACCURATE, COMPLETE, CURRENT, ERROR-FREE, OR CLINICALLY VALIDATED; (c)

ANY WARRANTY THAT ANNOTATION DATA REFLECTS THE CORRECT IDENTIFICATION OF ANATOMICAL STRUCTURES, PROCEDURAL PHASES, OR RISK PATTERNS IN ANY GIVEN SURGICAL VIDEO; (d) ANY WARRANTY THAT THE PLATFORM WILL BE UNINTERRUPTED, SECURE, OR FREE FROM ERRORS OR DEFECTS; AND (e) ANY WARRANTY AS TO THE FITNESS OF THE CONTENT OR SERVICES FOR ANY CLINICAL, DIAGNOSTIC, OR REGULATORY PURPOSE.

4.1 Not a Medical Device (Pre-Clearance)

The Services and Content provided under this Agreement are pre-commercial research and educational tools only. They are not FDA-cleared medical devices and are not intended, designed, or validated for use in clinical decision-making during live surgical procedures. Content is produced using a combination of expert manual review and AI-assisted annotation tools; neither process constitutes clinical validation. No annotation, label, structural identification, or any other output available through the Platform should be relied upon for intraoperative clinical decision-making. The operating surgeon retains sole professional responsibility for all surgical decisions. Dynamic annotation layers (including procedural phase markers, risk pattern identifiers, and workflow deviation alerts) are potential future product features and are not included in the current pre-commercial offering.

4.2 Educational Use Only

Content is provided exclusively for surgical education, training, and research as described in Section 2.2. MAP65 makes no representation that the techniques, approaches, or anatomical depictions shown in any Content represent the standard of care, are appropriate for any particular patient or clinical situation, or have been validated in controlled clinical studies.

4.3 No Endorsement

Inclusion of any institution, surgeon, or procedure in MAP65 Content does not constitute endorsement by MAP65 of that institution's, surgeon's, or procedure's quality, safety, or outcomes.

5. Limitation of Liability

TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW:

- IN NO EVENT SHALL MAP65 BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS, LOSS OF DATA, LOSS OF GOODWILL, BUSINESS INTERRUPTION, OR COST OF SUBSTITUTE SERVICES, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, EVEN IF MAP65 HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
- MAP65'S TOTAL CUMULATIVE LIABILITY ARISING OUT OF OR RELATING TO THESE TERMS OR THE SERVICES, UNDER ANY CAUSE OF ACTION, SHALL NOT EXCEED THE TOTAL FEES PAID BY SUBSCRIBER TO MAP65 IN THE TWELVE (12) MONTHS PRECEDING THE EVENT GIVING RISE TO THE CLAIM.
- THE FOREGOING LIMITATIONS APPLY REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR OTHERWISE, AND SHALL SURVIVE FAILURE OF AN EXCLUSIVE REMEDY.

Some jurisdictions do not permit the exclusion or limitation of certain implied warranties or consequential damages. In such jurisdictions, the above exclusions and limitations apply to the maximum extent permitted by applicable law.

6. Indemnification

Subscriber shall defend, indemnify, and hold harmless MAP65, its officers, directors, employees, contractors, and licensors from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorneys' fees) arising from or relating to:

- Subscriber's or any Named User's use of the Services or Content in violation of these Terms;

- Subscriber's breach of any representation or warranty in these Terms, including the representation that Subscriber-Submitted Content has been De-Identified;
- Any clinical or surgical decision made by any Named User, whether or not such decision was informed by Content accessed through the Platform;
- Any failure by Subscriber to obtain required institutional approvals, IRB authorization, patient consent, or other authorization required for submission of Subscriber-Submitted Content; or
- Any third-party claim that Subscriber-Submitted Content infringes any third party's intellectual property, privacy, or other rights.

7. Privacy, HIPAA, and Data Security

7.1 No PHI Accepted

MAP65 does not accept Protected Health Information (PHI) as defined under HIPAA (45 C.F.R. § 160.103). All Subscriber-Submitted Content must be De-Identified by Subscriber prior to upload. Subscriber is solely responsible for De-Identification and for compliance with HIPAA and all applicable data protection laws with respect to Subscriber-Submitted Content.

7.2 Platform User Data

MAP65 collects and processes account information and platform usage data (login events, playback session records, search queries) for Named Users to operate and improve the Platform. This data is processed in accordance with MAP65's Privacy Policy (www.MAP65.com/privacy). MAP65 does not sell user data to third parties. Playback session logs may be used in aggregated, de-identified form for analytics and investor reporting.

7.3 Business Associate Agreement

If Subscriber's institution determines that a Business Associate Agreement (BAA) is required for use of the Platform, Subscriber should contact Partners@MAP65.com before initiating a Subscription. MAP65 will execute a BAA with Covered Entities where required; however, a BAA does not modify Subscriber's obligation to De-Identify content before submission.

7.4 Security

MAP65 implements reasonable technical and organizational security measures designed to protect the Platform and its data against unauthorized access, including encryption in transit (TLS 1.2+), encryption at rest (AES-256), role-based access controls, and multi-factor authentication for administrative accounts. MAP65 does not represent that the Platform is free from all security vulnerabilities. Subscriber is responsible for maintaining the confidentiality of Named User credentials.

8. Post-FDA Clearance Discount

Subscribers in good standing (all fees paid, no material breach) at the time of FDA clearance of the Second Surgeon platform are entitled to the post-clearance discount at the percentage corresponding to their Subscription tier at the time of signing (Tier 1 — Associate: 25%; Tier 2 — Partner: 35%; Tier 3 — Founder: 50%), applied on a per-robot, per-case basis to MAP65's then-current list pricing for the Post-Clearance Product. This discount applies to the first commercial subscription contract executed by Subscriber for the Post-Clearance Product and is not transferable, not cumulative with other discounts, and not redeemable for cash. MAP65 makes no representation regarding the timing of FDA clearance or that clearance will be obtained. The discount right terminates if Subscriber's Clinical Partners Program Subscription lapses or is terminated for cause prior to FDA clearance.

9. Term, Renewal, and Termination

9.1 Term

The Subscription Term commences on the subscription start date specified in the applicable Quotation and continues for a minimum of two (2) years. This minimum term is non-cancelable by Subscriber except as expressly provided in

Section 9.2, and Subscriber's obligation to pay the total fees applicable to the minimum term is fixed as of the subscription start date regardless of whether such fees are invoiced annually, in a single upfront payment, or otherwise as specified in the applicable Quotation or Order Form. Following the initial term, the Subscription renews automatically for successive one-year periods unless either party provides written notice of non-renewal at least sixty (60) days before the end of the then-current term.

9.2 Termination for Cause

Either party may terminate the Subscription immediately upon written notice if the other party materially breaches these Terms and fails to cure such breach within thirty (30) days after receiving written notice specifying the breach in reasonable detail. MAP65 may additionally suspend or terminate Platform access immediately, without cure period, if Subscriber: (a) submits content containing PHI; (b) distributes or commercially exploits Content in violation of Section 2.3; or (c) uses the Platform or Content in a manner posing a risk of patient harm.

9.3 Effect of Termination

Upon termination or expiration: (a) all Subscription rights and Platform access terminate immediately; (b) Subscriber's license to view and use Content ceases; (c) MAP65 retains all rights in Annotation Data and De-Identified Subscriber-Submitted Content as set forth in Section 3.3; (d) no refund of prepaid fees (whether invoiced annually, as a single upfront payment for the minimum term, or otherwise) will be issued unless termination is by Subscriber for MAP65's uncured material breach; and (e) accrued payment obligations survive termination.

10. General Provisions

10.1 Governing Law and Dispute Resolution

These Terms are governed by the laws of the State of Delaware, without regard to conflicts of law principles. Any dispute arising out of or relating to these Terms or the Services that cannot be resolved by good-faith negotiation within 30 days shall be submitted to binding arbitration administered by the American Arbitration Association (AAA) under its Commercial Arbitration Rules. The seat of arbitration shall be Wilmington, Delaware. The arbitrator's award shall be final and may be entered as a judgment in any court of competent jurisdiction. Notwithstanding the foregoing, either party may seek injunctive or other equitable relief in any court of competent jurisdiction to protect intellectual property rights or prevent irreparable harm pending arbitration.

10.2 Entire Agreement

These Terms, together with the applicable Quotation or Order Form, constitute the entire agreement between the parties regarding the subject matter herein and supersede all prior negotiations, representations, or agreements, oral or written. No terms in any Subscriber-issued purchase order or similar document shall modify or supplement these Terms unless separately agreed in a signed writing by an authorized MAP65 officer.

10.3 Modifications

MAP65 may modify these Terms at any time by posting updated Terms at www.MAP65.com/terms. MAP65 will provide at least thirty (30) days' notice of material changes via email to the Billing Contact and via in-platform notification. Continued use of the Services after the effective date of any modification constitutes acceptance. If Subscriber objects to a material modification, Subscriber may terminate the Subscription at the end of the then-current annual period without penalty.

10.4 Assignment

Subscriber may not assign these Terms or any rights hereunder without MAP65's prior written consent. MAP65 may assign these Terms in connection with a merger, acquisition, corporate reorganization, or sale of all or substantially all of its assets, provided the assignee assumes all obligations herein.

10.5 Severability

If any provision of these Terms is found invalid or unenforceable, that provision will be modified to the minimum extent necessary to make it enforceable, and the remaining provisions will continue in full force.

10.6 Waiver

No failure or delay by either party in exercising any right under these Terms constitutes a waiver of that right. Waivers must be in writing to be effective.

10.7 Force Majeure

MAP65 will not be liable for any delay or failure in performance resulting from causes beyond its reasonable control, including acts of God, government actions, pandemic, natural disaster, or third-party infrastructure failure. MAP65 will use commercially reasonable efforts to resume service as soon as practicable.

10.8 Notices

Notices to MAP65 under these Terms shall be sent to: MAP65, Inc., [Address], Attn: Legal, with a copy by email to Partners@MAP65.com. Notices to Subscriber shall be sent to the Billing Contact email on file. Notices are effective upon confirmed delivery.

10.9 Relationship of the Parties

The parties are independent contractors. These Terms do not create a partnership, joint venture, employment, or agency relationship. Neither party has authority to bind the other.

10.10 Export Compliance

Subscriber agrees to comply with all applicable U.S. export control laws and regulations. Subscriber will not access or use the Platform or Content from any jurisdiction subject to U.S. comprehensive sanctions without prior written authorization from MAP65.

Contact

For questions about these Terms, data use, or business associate agreements:

General Inquiries	Partners@MAP65.com
Legal / Compliance	Legal@MAP65.com (or Partners@MAP65.com, attn: Legal)
Data Inquiries	Partners@MAP65.com, attn: Data Governance
Website	www.MAP65.com
Terms URL	www.MAP65.com/terms
Privacy Policy URL	www.MAP65.com/privacy